Stockscreener 앱 받기
23.99
0.97%
0.23
시간 외 거래:
23.99
전일 마감가:
$23.76
열려 있는:
$23.6
하루 거래량:
224.37K
Relative Volume:
0.73
시가총액:
$606.93M
수익:
-
순이익/손실:
$-61.59M
주가수익비율:
-8.7991
EPS:
-2.7264
순현금흐름:
-
1주 성능:
-3.81%
1개월 성능:
-0.87%
6개월 성능:
+51.07%
1년 성능:
+0.00%
1일 변동 폭
$23.05
$24.24
1주일 범위
$23.05
$27.55
52주 변동 폭
$13.36
$27.55
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
명칭
Lb Pharmaceuticals Inc
전화
917-450-6581
주소
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
23.99 | 601.11M | 0 | -61.59M | 0 | -2.7264 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 개시 | Roth Capital | Buy |
| 2025-10-06 | 개시 | Leerink Partners | Outperform |
| 2025-10-06 | 개시 | Piper Sandler | Overweight |
| 2025-10-06 | 개시 | Stifel | Buy |
Lb Pharmaceuticals Inc 주식(LBRX)의 최신 뉴스
LBRX: LB-102 advances toward pivotal data in major CNS indications, fully funded through 2029 - TradingView
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 4.6%Should You Sell? - MarketBeat
LB Pharmaceuticals director Zachary Prensky to retire after 2026 annual meeting - Investing.com
LB Pharmaceuticals Announces Director Zachary Prensky’s Planned Retirement - TipRanks
Boxer Capital Management LLC Acquires Shares of 70,000 LB Pharmaceuticals Inc $LBRX - MarketBeat
Commodore Capital LP Invests $23.69 Million in LB Pharmaceuticals Inc $LBRX - MarketBeat
200,000 Shares in LB Pharmaceuticals Inc $LBRX Bought by Baker BROS. Advisors LP - MarketBeat
300,000 Shares in LB Pharmaceuticals Inc $LBRX Acquired by Nan Fung Group Holdings Ltd - MarketBeat
100,000 Shares in LB Pharmaceuticals Inc $LBRX Purchased by Integral Health Asset Management LLC - MarketBeat
LB Pharmaceuticals appoints Robert Lenz to board of directors By Investing.com - Investing.com Nigeria
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 12-Month HighShould You Buy? - MarketBeat
Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight - The Malaysian Reserve
LB Pharmaceuticals (LBRX) director receives 20,000 stock options vesting 2027–2029 - Stock Titan
LB Pharmaceuticals (LBRX) director Robert Lenz files initial Form 3 - Stock Titan
LB Pharmaceuticals adds neuroscience leader to board, governance - TipRanks
LB Pharmaceuticals (Nasdaq: LBRX) names new director and COO - Stock Titan
LB Pharmaceuticals Inc Approves the Promotion of Gad Soffer, the Chief Business Officer, to the Position of Chief Operating and Business Officer, Effective March 4, 2026 - marketscreener.com
Certain Stock Options of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026. - marketscreener.com
3,433,470 Common Stock of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026. - marketscreener.com
LB Pharmaceuticals appoints Robert Lenz to board of directors - Investing.com
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors - Bitget
LB Pharmaceuticals Inc (NASDAQ:LBRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
LB Pharmaceuticals Inc (LBRX) Dividend News Alerts - DividendInvestor.com
LB Pharmaceuticals Inc’s Lock-Up Period Will Expire on March 10th (NASDAQ:LBRX) - Defense World
LB Pharmaceuticals to Participate in Upcoming March Investor Events - Bitget
LBRX SEC FilingsLB Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week HighTime to Buy? - MarketBeat
JPMorgan Chase & Co. Buys Shares of 1,032,603 LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals Inc's (NASDAQ:LBRX) Lock-Up Period Set To End on March 10th - MarketBeat
LB Pharmaceuticals Inc’s (NASDAQ:LBRX) Lock-Up Period Set To End on March 10th - Defense World
LBRX Technical Analysis & Stock Price Forecast - Intellectia AI
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - marketscreener.com
Analysts Conflicted on These Healthcare Names: Merit Medical Systems (MMSI), LB Pharmaceuticals, Inc. (LBRX) and Cytokinetics (CYTK) - The Globe and Mail
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of “Hold” by Analysts - Defense World
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Analysts Are Bullish on Top Healthcare Stocks: Pelthos Therapeutics (PTHS), GoodRx Holdings (GDRX) - The Globe and Mail
Neuro drug developer LB Pharma seeks $300M+ valuation in U.S. IPO - MSN
LB Pharmaceuticals Announces $100 Million Private Placement Financing - The Globe and Mail
LB Pharmaceuticals stock rises on $100M financing - MSN
LB Pharmaceuticals announces $100.0 million private placement - marketscreener.com
LB Pharmaceuticals Signs Multiple Material Agreements - TradingView
Lb Pharmaceuticals Announces $100.0 Million Private Placement - TradingView
LB Pharmaceuticals Announces $100.0 Million Private Placement - The Manila Times
Sector Update: Health Care - marketscreener.com
LB Pharmaceuticals Advances LB-102 Into Long-Term Phase 3 Safety Study for Schizophrenia - TipRanks
Lb Pharmaceuticals Inc (LBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):